Locations
San Francisco, CA, USA · South San Francisco, CA, USA
industry
Biotechnology · DeepTech · Health
Size
11-50 employees
Stage
Series B
founded in
2019
Ig Genix, Inc. is a clinical-stage antibody discovery and development company focused on solving allergies and other immunological diseases. Utilizing their SEQ SIFTER™ antibody discovery platform, they develop innovative products like IGNX001, a first-in-class antibody targeting food allergies, specifically peanut allergies. Their unique approach aims to provide faster and more sustained clinical responses, positioning them at the forefront of allergy immunology. With several programs in their pipeline targeting both food and environmental allergies, Ig Genix is well-positioned to make significant advancements in the treatment of allergic diseases.
Something looks off?